Series B - AgomAb Therapeutics
Investment Firm
Overview
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
Announced Date
Jul 13, 2022
Funding Type
Series B
Highlights
Location
Europe
Social
Investor Lead
N/A
Participant Investors
1
| Investor Name |
|---|
Round Details and Background
AgomAb Therapeutics raised $38531817 on 2022-07-13 in Series B
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
Company Funding History
4
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Mar 10, 2021 |  Series B - AgomAb Therapeutics | 8 | - | 74.0M |
| Apr 03, 2019 | Series A - AgomAb Therapeutics | 5 | - | 23.6M |
| Jul 13, 2022 | Series B - AgomAb Therapeutics | 3 | - | 38.5M |
| Oct 11, 2023 | Series C - AgomAb Therapeutics | 12 | - | 100.8M |
Recent Activity
There is no recent news or activity for this profile.